Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials

Cliniques Universitaires Saint-Luc, Brussels

UZ Antwerpen, Edegem

The Alfred Hospital, Melbourne

Samsung Medical Center - PPDS, Seoul

Chulalongkorn University, Pathum Wan

National Cancer Center, Goyang-si

"Institutul National de Endocrinologie C. I. Parhon", Bucharest

Eisai trial site 2, Essen

Karmanos Cancer Institute, Detroit

Azienda Ospedaliero Universitaria Pisana, Pisa

Northwestern University, Chicago

Harbor UCLA Medical Center, Torrance

Eisai trial site 1, Würzburg

Sun Yat-sen University, Cancer Center, Guangzhou

Affiliated Hospital of Guilin Medical University, Guilin

Harbin Medical University Cancer Hospital, Haerbin

Henan Cancer Hospital, Zhengzhou

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

Hunan Cancer Hospital, Changsha

Jiangsu Cancer Hospital, Nanjing

Nanjing First Hospital, Nanjing

The First Hospital of Jilin University, Changchun

No.10 People of Shanghai, Shanghai

West China School of Medicine/West China Hospital, Sichuan University, Chengdu

Tianjin Medical University Cancer Institute & Hospital, Tianjin

Zhejiang Cancer Hospital, Hangzhou

Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam

Centrum Onkologii Instytut im.Marii Sklodowskiej Curie-Oddzial w Gliwicach, Gliwice